Relaxed regulations, misinformation, and a big potential payout are reminiscent of the conditions that cultivated Theranos

In November 2015, the U.S. House of Representatives held a hearing about draft guidance from the U.S. Food and Drug Administration (FDA) about closing a regulatory loophole exploited by Theranos. However, the draft guidance was never put into law, with one congressman objecting, “Why in the world would a lab…

Tyler Shultz

CEO and Co-founder Flux Biosciences, Theranos Whistleblower

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store